RenovoRx

12/05/2025

Reminder: RenovoRx CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on Tuesday, December 9th at 12:30 P.M. ET. For webcast details, visit: https://bit.ly/3XygbI6

12/04/2025

RenovoRx will host a panel discussion and dinner with experts in the field of oncology including Michael Pishvaian, MD, PhD as moderator, and Pashtoon Kasi, MD, MS, Jonathan Kessler, MD, Dae Won Kim, MD and John Rhee, MD on Thursday, January 8th during the 2026 ASCO Gastrointestinal Cancers Symposium. Please email sstafford@renovorx.com to RSVP and receive additional information.

12/03/2025

Moffitt Cancer Center spotlighted one patient's journey of being treated with a new treatment option designed for localized, targeted drug-delivery that includes RenovoRx's TAMP™ therapy platform and RenovoCath® device. Read more: https://bit.ly/3MCgDTi

*RenovoCath is currently cleared for the indication below. The Company is evaluating its novel combination oncology product candidate (intra-arterial gemcitabine, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. Based on completed studies, intra-arterial delivery of chemotherapy via Trans-Arterial Micro-Perfusion (TAMP™), which targets delivery of treatment in proximity to the tumor tissue within the pancreas using the vasa vasorum pathway, reduced tolerability issues associated with systemic chemotherapy and presented early signals of improved patient survival. The study, called TIGeR-PaC (“Intra-Arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC”), is the evaluating the combination oncology product candidate (IAG) which is not yet approved by FDA for this use and not yet available for commercial sale.

Indication for Use: RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath is intended for general intravascular use in the peripheral vasculature in arteries 3mm and larger. The RenovoCath is intended for use in arteries from 3mm in diameter for vessel entry and to occlude vessels ranging between 3mm to 11mm in diameter. The diagnostic and/or therapeutic agents are to be used in accordance with specifications outlined by the respective agent manufacturer. For detailed information on RenovoCath including warnings, precautions, and contraindications, please refer to the product IFU on the RenovoRx website:https://renovorx.com/wp-content/uploads/2025/04/IFU-10004-Rev.-G-Universal-IFU.pdf

12/02/2025

NBC News highlighted the potential of RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, designed for targeted drug-delivery via the RenovoCath® device in difficult-to-treat tumors, like . Watch the interview with Dr. Gregory Tiesi, Medical Director of Hepatobiliary Surgery, about his patient receiving treatment with TAMP at Hackensack Meridian Jersey Shore University Medical Center: https://bit.ly/4pHf2dl

*RenovoCath is currently cleared for the indication below. The Company is evaluating its novel combination oncology product candidate (intra-arterial gemcitabine, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. Based on completed studies, intra-arterial delivery of chemotherapy via Trans-Arterial Micro-Perfusion (TAMP™), which targets delivery of treatment in proximity to the tumor tissue within the pancreas using the vasa vasorum pathway, reduced tolerability issues associated with systemic chemotherapy and presented early signals of improved patient survival. The study, called TIGeR-PaC (“Intra-Arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC”), is evaluating the combination oncology product candidate (IAG) which is not yet cleared or approved by FDA for this use and not yet available for commercial sale.

Indication for Use: RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath is intended for general intravascular use in the peripheral vasculature in arteries 3mm and larger. The RenovoCath is intended for use in arteries from 3mm in diameter for vessel entry and to occlude vessels ranging between 3mm to 11mm in diameter. The diagnostic and/or therapeutic agents are to be used in accordance with specifications outlined by the respective agent manufacturer. For detailed information on RenovoCath including warnings, precautions, and contraindications, please refer to the product IFU on the RenovoRx website:https://renovorx.com/wp-content/uploads/2025/04/IFU-10004-Rev.-G-Universal-IFU.pdf

Pancreatic cancer is a disease that’s often deadly, but a new treatment is showing promise at a New Jersey hospital. NBC10’s Ted Greenberg explains how it has made a difference for one man who thought he was out of options.

12/01/2025

RenovoRx CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on Tuesday, December 9th at 12:30 P.M. ET. Shaun will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath® as a standalone, targeted drug-delivery device across both new and repeat customers. He will also discuss recent advancements in the Company’s clinical research and scientific programs including the ongoing Phase III TIGeR-PaC clinical trial and post-marketing registry study. For details: https://bit.ly/4p4FNbC

11/25/2025

This month, join us in raising awareness and supporting advancements in cancer care. RenovoRx is committed to improving the standard of care in treatment for patients diagnosed with difficult-to-treat cancers, like . Learn more about our work: https://bit.ly/49zQls2

11/20/2025

Today, on , we stand with the patients, families, and healthcare professionals facing one of the most challenging cancers to treat. RenovoRx is on a mission to transform the lives of cancer patients via innovative targeted therapeutic drug-delivery. Learn about our TAMP™ therapy platform: https://bit.ly/3urdTiK

11/20/2025

Tune-in today, November 20th, at 2:00 PM ET, for RenovoRx CEO, Shaun Bagai's presentation at the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase. For webcast details: https://bit.ly/4i8ZEE1

11/19/2025

Medical Product Outsourcing highlighted the first clinical procedure successfully completed in RenovoRx's RR5 Post-Marketing Registry Study at University of Vermont Cancer Center, a major milestone for the Company. The registry study is assessing the safety and effectiveness of RenovoCath®, a patented, FDA-cleared drug-delivery device, in real-world settings. Learn more: https://bit.ly/4qFPApL

RenovoRx announces the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry study.

11/19/2025

RenovoRx CEO, Shaun Bagai, will participate in the Alliance Global Partners (AGP) Emerging AgBiotech/Bio-Solutions Virtual Showcase tomorrow, November 20th, at 2:00 PM ET. Shaun will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. He will also discuss recent advancements in the Company’s clinical research and scientific programs including the ongoing Phase III TIGeR-PaC clinical trial and post-marketing registry study. For details: https://bit.ly/3K2nZ1E

11/14/2025

RenovoRx shared an update on the ongoing Phase III TIGeR-PaC trial for drug-delivery in locally advanced pancreatic cancer. Read more: https://bit.ly/3LGpdzZ

11/14/2025

Dr. Ripal Gandhi, interventional radiologist at Miami Cancer Institute and Miami Cardiac & Vascular Institute, will present at the 2025 AIMsymposium during Session 6: “Clinical Trials in Pancreas Cancer: IRE, RenovoRx and Others” and participate in a panel discussion on Thursday, November 20th. Dr. Gandhi will discuss RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the ongoing Phase III TIGeR‑PaC clinical trial in . For event details: https://bit.ly/4pen8df